Because of its extensive expression and immunosuppressive function in most cancers, TGF-β has been combined with PD-L1 to develop anti-TGF-β/PD-L1 bispecific antibodies such as M7824 [121], SHR-1701 [122], and YM101 [123]. This evidence concerns the gene CD274 and cancer.